Project Summary

There are about 300 million dry eye patients nationwide and the domestic market value of dry eye drops is more than 15 billion. The number of patients and the market value increase by 10-20% every year. Antibiotic eye drops are the first choice for the treatment of dry eye, but antibiotics should not be used repeatedly. The other kind of eye drops that can be used daily is artificial tears, but it has no anti-inflammatory effect. This project develops a new recombinant protein artificial tear with anti-inflammatory effect, which can be used as an anti-inflammatory drug for long-term repeated use, as well as an supplement of artificial tear , and has a unique effect on improving ocular surface injury.

 

At the same time, our company will also develop another first class global innovative biological medicines using the same protein, which can simultaneously reduce blood pressure, blood sugar, blood lipids, and enhance cardiovascular function.